







UNINTENDED CONSEQUENCES WERE NEVER UNANTICIPATED CONSEQUENCES





and cost-effective*	
A manuscript in the Annals of Internal Medicine indicated that providing naloxone to heroin users is robustly cost-effective and possibly cost-saving. Investigators believe similar results	
apply to other opioid users. Cost: Benefit:	
164 naloxone scripts = 1 prevented death	
per quality-adjusted life-year gained	
Emerging data suggests that providing naloxone may encourage patients to be safer with their opioid use. If this is the case, the intervention would be cost-saving and 36 prescriptions would prevent one death.	
Silde courtesy of Phillip Coffin & Emily Behar	
Evidence challenges & ethical considerations • RCTs	
Difficult measures	
Network effect	
Relatively weak design, but results all in same direction	
Image courtesy: Scottish Drugs Forum	
BEST PRACTICES	
DESTRINCTIONS	





People who use drugs

People who use drugs

Other incidental bystanders

Summoned responders

Summoned responders


Description:

Experiencing incarceration
(Binswanger, 2013)
Entering & exiting treatment for OUD
(Strang, 2003)
Experiencing homelessness
(Baggett, 2012)
Living with HIV/ AIDS
(Green, 2012)

MODELS, ADAPTATIONS & CONSIDERATIONS

Enrollment locations: 2008-2014 (first half) Using, In Treatment, or In Recovery Non Users (family, friends, staff) Detox Community Meeting Drop-In Center Syringe Access Residential / 1/2 way house Inpatient / ED / Outpatient Methadone Clinic Home Visit / Shelter / Street Outreach Other 0 1000 2000 3000 4000 5000 6000 7000 Data from people with location reported: Users: 17,494 Non-Users: 9,275 Currently > 28,000 enrollees and >3300 overdose rescues documented MDPH Program data

Challenges for community programs Naloxone cost is increasing, funding is minimal Missing people who don't identify as drug users, but have high risk Missing people who may periodically misuse opioids=no tolerance Co-prescribe naloxone with opioids for pain Co-prescribe with methadone/ buprenorphine for addiction Insurance should fund Increase patient, provider & pharmacist awareness Universalize overdose risk







Models for OAT and detox		
Model	Advantages	Disadvantages
Staff provide OEND on-site	 Good access to OEND OD prevention integrated 	Patients may not disclose risk
2. Outside staff provide OEND on-site	 OD prevention integrated Interagency cooperation Low burden on staff 	Community OEND program needed
3. OE provided onsite, naloxone received off-site	OD prevention integrated Interagency cooperation	Increased patient burden to get naloxone
4. Outside staff recruit near MMT or detox	Confidential access to OD prevention	OD prevention not re- enforced in treatment Not all patients reached Walley, 2013














Sessions with PWUD

- VALIDATE group member's experiences
- Ask what they know about each topic
- Clarify "old school" methods ("myth busting")
 "If you tried to help you did the right thing."
- Respect confidentiality
- Discuss options, plans
- Monitor group domination
- Be prepared for a range of emotions
- Refer when appropriate



Considerations for families & loved ones Referrals People behind the data Fear, anger, sorrow, regret, shame Overdose-SUD context Living @ home Advocacy & stories People who have lost someone are different than people who have loved ones currently struggling





Conclusions

- "What is the goal?" affects intervention design
- Evidence says people who use drugs
- The more naloxone in a community, the better
- Wildly adaptable
- Challenge stigma

